1
|
Smith D, Helgason H, Sulem P, Bjornsdottir US, Lim AC, Sveinbjornsson G, Hasegawa H, Brown M, Ketchem RR, Gavala M, Garrett L, Jonasdottir A, Jonasdottir A, Sigurdsson A, Magnusson OT, Eyjolfsson GI, Olafsson I, Onundarson PT, Sigurdardottir O, Gislason D, Gislason T, Ludviksson BR, Ludviksdottir D, Boezen HM, Heinzmann A, Krueger M, Porsbjerg C, Ahluwalia TS, Waage J, Backer V, Deichmann KA, Koppelman GH, Bønnelykke K, Bisgaard H, Masson G, Thorsteinsdottir U, Gudbjartsson DF, Johnston JA, Jonsdottir I, Stefansson K. A rare IL33 loss-of-function mutation reduces blood eosinophil counts and protects from asthma. PLoS Genet 2017; 13:e1006659. [PMID: 28273074 PMCID: PMC5362243 DOI: 10.1371/journal.pgen.1006659] [Citation(s) in RCA: 89] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2016] [Revised: 03/22/2017] [Accepted: 02/26/2017] [Indexed: 02/07/2023] Open
Abstract
IL-33 is a tissue-derived cytokine that induces and amplifies eosinophilic inflammation and has emerged as a promising new drug target for asthma and allergic disease. Common variants at IL33 and IL1RL1, encoding the IL-33 receptor ST2, associate with eosinophil counts and asthma. Through whole-genome sequencing and imputation into the Icelandic population, we found a rare variant in IL33 (NM_001199640:exon7:c.487-1G>C (rs146597587-C), allele frequency = 0.65%) that disrupts a canonical splice acceptor site before the last coding exon. It is also found at low frequency in European populations. rs146597587-C associates with lower eosinophil counts (β = -0.21 SD, P = 2.5×10–16, N = 103,104), and reduced risk of asthma in Europeans (OR = 0.47; 95%CI: 0.32, 0.70, P = 1.8×10–4, N cases = 6,465, N controls = 302,977). Heterozygotes have about 40% lower total IL33 mRNA expression than non-carriers and allele-specific analysis based on RNA sequencing and phased genotypes shows that only 20% of the total expression is from the mutated chromosome. In half of those transcripts the mutation causes retention of the last intron, predicted to result in a premature stop codon that leads to truncation of 66 amino acids. The truncated IL-33 has normal intracellular localization but neither binds IL-33R/ST2 nor activates ST2-expressing cells. Together these data demonstrate that rs146597587-C is a loss of function mutation and support the hypothesis that IL-33 haploinsufficiency protects against asthma. Only a few genes have been found to play a role in asthma. These include the genes IL33 and IL1RL1, and sequence variants in the human genome close to these genes were initially found to affect the number of eosinophils, cells that play a role in inflammation of the airways in asthma. Based on this knowledge, we decided to use high resolution sequencing technology to search for variants in these genes that cause changes in structure and function of the proteins they encode. We found a rare (0.65%) sequence variant in the IL33 gene, that causes less production of the IL33 protein and some of the protein formed lacks the capacity to bind to its receptor on cells and promote inflammation. This rare mutation causes reduced number of eosinophils in blood and protects against asthma. These results suggest that drugs that could interfere with the inflammatory activity of the IL33 protein may be beneficial for treatment of asthma.
Collapse
Affiliation(s)
- Dirk Smith
- Amgen Inc., Discovery Research, South San Francisco, California, United States of America
| | - Hannes Helgason
- deCODE genetics / Amgen Inc., Reykjavík, Iceland
- School of Engineering and Natural Sciences, University of Iceland, Reykjavik, Iceland
| | | | - Unnur Steina Bjornsdottir
- Department of Medicine, Landspitali, The National University Hospital of Iceland, Reykjavik, Iceland
| | - Ai Ching Lim
- Amgen Inc., Discovery Research, South San Francisco, California, United States of America
| | | | - Haruki Hasegawa
- Amgen Inc., Discovery Research, South San Francisco, California, United States of America
| | - Michael Brown
- Amgen Inc., Discovery Research, South San Francisco, California, United States of America
| | - Randal R. Ketchem
- Amgen Inc., Discovery Research, South San Francisco, California, United States of America
| | - Monica Gavala
- Amgen Inc., Discovery Research, South San Francisco, California, United States of America
| | - Logan Garrett
- Amgen Inc., Discovery Research, South San Francisco, California, United States of America
| | | | | | | | | | | | - Isleifur Olafsson
- Department of Clinical Biochemistry, Landspitali, The National University Hospital of Iceland, Reykjavik, Iceland
| | - Pall Torfi Onundarson
- Laboratory Hematology, Landspitali, The National University Hospital of Iceland, Reykjavik, Iceland
- Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland
| | - Olof Sigurdardottir
- Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland
- Department of Clinical Biochemistry, Akureyri Hospital, Akureyri, Iceland
| | - David Gislason
- Department of Respiratory Medicine and Sleep, Landspitali, The National University Hospital of Iceland, Reykjavik, Iceland
| | - Thorarinn Gislason
- Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland
- Department of Respiratory Medicine and Sleep, Landspitali, The National University Hospital of Iceland, Reykjavik, Iceland
| | - Bjorn Runar Ludviksson
- Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland
- Department of Immunology, Landspitali, The National University Hospital of Iceland, Reykjavik, Iceland
| | - Dora Ludviksdottir
- Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland
- Department of Respiratory Medicine and Sleep, Landspitali, The National University Hospital of Iceland, Reykjavik, Iceland
| | - H. Marike Boezen
- GRIAC research institute, Groningen, The Netherlands
- University Medical Center Groningen, University of Groningen, Department of Epidemiology, Groningen, The Netherlands
| | - Andrea Heinzmann
- Center for Pediatrics, Department of General Pediatrics, Adolescent Medicine and Neonatology, Medical Center – University of Freiburg, Faculty of Medicine, Freiburg, Germany
| | - Marcus Krueger
- Center for Pediatrics, Department of General Pediatrics, Adolescent Medicine and Neonatology, Medical Center – University of Freiburg, Faculty of Medicine, Freiburg, Germany
| | - Celeste Porsbjerg
- Department of Respiratory Medicine, Bispebjerg University Hospital, Copenhagen University, Copenhagen, Denmark
| | - Tarunveer S. Ahluwalia
- COPSAC (Copenhagen Prospective Studies on Asthma in Childhood), Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
| | - Johannes Waage
- COPSAC (Copenhagen Prospective Studies on Asthma in Childhood), Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
| | - Vibeke Backer
- Department of Respiratory Medicine, Bispebjerg University Hospital, Copenhagen University, Copenhagen, Denmark
| | - Klaus A. Deichmann
- Center for Pediatrics, Department of General Pediatrics, Adolescent Medicine and Neonatology, Medical Center – University of Freiburg, Faculty of Medicine, Freiburg, Germany
| | - Gerard H. Koppelman
- GRIAC research institute, Groningen, The Netherlands
- University Medical Center Groningen, University of Groningen, Department of Pediatric Pulmonology and Pediatric Allergology, Beatrix Children's Hospital, Groningen, The Netherlands
| | - Klaus Bønnelykke
- COPSAC (Copenhagen Prospective Studies on Asthma in Childhood), Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
| | - Hans Bisgaard
- COPSAC (Copenhagen Prospective Studies on Asthma in Childhood), Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
| | - Gisli Masson
- deCODE genetics / Amgen Inc., Reykjavík, Iceland
| | - Unnur Thorsteinsdottir
- deCODE genetics / Amgen Inc., Reykjavík, Iceland
- Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland
| | - Daniel F. Gudbjartsson
- deCODE genetics / Amgen Inc., Reykjavík, Iceland
- School of Engineering and Natural Sciences, University of Iceland, Reykjavik, Iceland
| | - James A. Johnston
- Amgen Inc., Discovery Research, South San Francisco, California, United States of America
| | - Ingileif Jonsdottir
- deCODE genetics / Amgen Inc., Reykjavík, Iceland
- Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland
- Department of Immunology, Landspitali, The National University Hospital of Iceland, Reykjavik, Iceland
- * E-mail: (KS); (IJ)
| | - Kari Stefansson
- deCODE genetics / Amgen Inc., Reykjavík, Iceland
- Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland
- * E-mail: (KS); (IJ)
| |
Collapse
|
2
|
Koca SS, Pehlivan Y, Kara M, Alibaz-Oner F, Oztuzcu S, Yilmaz N, Cetin GY, Kisacik B, Ozgen M, Pamuk ON, Direskeneli H, Sayarlioglu M, Onat AM. The IL-33 gene is related to increased susceptibility to systemic sclerosis. Rheumatol Int 2016; 36:579-84. [PMID: 26743213 DOI: 10.1007/s00296-015-3417-8] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2015] [Accepted: 12/23/2015] [Indexed: 12/26/2022]
Abstract
Systemic sclerosis (SSc) is a chronic inflammatory disease characterized by widespread fibrosis of the skin and several visceral organs. The pro-fibrotic potential of interleukin (IL)-33 has been demonstrated by in both in vitro and in vivo settings; moreover, increased level of IL-33 has also been reported in patients with SSc. Therefore, the aim of the present study was to detect the potential association of IL-33 gene polymorphisms on the susceptibility of SSc. A total of 300 SSc patients and 280 healthy controls (HC) were enrolled in this multicentric preliminary candidate gene study. DNA samples were harvested using an appropriate commercial DNA isolation kit. Four single nucleotide polymorphisms (SNPs) of IL-33 gene (rs7044343, rs1157505, rs11792633 and rs1929992) were genotyped using the appropriate commercial primer/probe sets on real-time PCR. There was no significant difference in terms of the allelic distributions and minor allele frequencies of evaluated four IL-33 polymorphisms between the SSc and HC groups (P > 0.05 for all). Moreover, the genotypic distributions of rs1157505, rs11792633 and rs1929992 polymorphisms were not significantly different (P > 0.05 for all). However, CC genotype of rs7044343 SNP was significantly higher in the SSc group compared to the HC group (P = 0.013, OR 1.75, 95 % CI 1.12-2.72). This preliminary candidate gene study demonstrates that rs7044343 polymorphism of IL-33 gene is associated with the susceptibility to the SSc in Turkish population. It may be suggested that IL-33 gene may be a candidate gene to research in SSc.
Collapse
Affiliation(s)
- Suleyman Serdar Koca
- Department of Rheumatology, Faculty of Medicine, Firat University, 23119, Elazig, Turkey.
| | - Yavuz Pehlivan
- Department of Rheumatology, Faculty of Medicine, Uludag University, Bursa, Turkey
| | - Murat Kara
- Department of Medical Genetics, Faculty of Medicine, Sitki Kocman University, Mugla, Turkey
| | - Fatma Alibaz-Oner
- Department of Rheumatology, Faculty of Medicine, Marmara University, Istanbul, Turkey
| | - Serdar Oztuzcu
- Department of Medical Genetics, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey
| | - Neslihan Yilmaz
- Department of Rheumatology, Sisli Florence Nightingale Hospital, Istanbul, Turkey
| | - Gozde Yildirim Cetin
- Department of Rheumatology, Faculty of Medicine, Sutcu Imam University, Kahramanmaras, Turkey
| | - Bunyamin Kisacik
- Department of Rheumatology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey
| | - Metin Ozgen
- Department of Rheumatology, Faculty of Medicine, 19 Mayis University, Samsun, Turkey
| | - Omer Nuri Pamuk
- Department of Rheumatology, Faculty of Medicine, Trakya University, Edirne, Turkey
| | - Haner Direskeneli
- Department of Rheumatology, Faculty of Medicine, Marmara University, Istanbul, Turkey
| | - Mehmet Sayarlioglu
- Department of Rheumatology, Faculty of Medicine, 19 Mayis University, Samsun, Turkey
| | - Ahmet Mesut Onat
- Department of Rheumatology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey
| |
Collapse
|